SeaStar Medical Sells SCD Tech to Unaffiliated Buyer
Ticker: ICUCW · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1831868
| Field | Detail |
|---|---|
| Company | Seastar Medical Holding CORP (ICUCW) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, strategic-shift, asset-sale
TL;DR
SeaStar Medical is selling its SCD tech to focus on other things. Deal expected Q3 2024.
AI Summary
SeaStar Medical Holding Corporation announced on July 5, 2024, that it has entered into a definitive agreement to sell its Selective Cytopheretic Device (SCD) technology and related assets to an unaffiliated third party. The transaction is expected to close in the third quarter of 2024. This sale is part of SeaStar Medical's strategic shift to focus on its other business segments.
Why It Matters
This sale represents a significant strategic pivot for SeaStar Medical, allowing them to divest a specific technology and potentially refocus resources on other areas of their business.
Risk Assessment
Risk Level: medium — The sale of a core technology and the company's strategic shift introduce uncertainty regarding future revenue streams and business focus.
Key Players & Entities
- SeaStar Medical Holding Corporation (company) — Registrant
- Selective Cytopheretic Device (SCD) technology (technology) — Asset being sold
- July 5, 2024 (date) — Date of agreement
- third quarter of 2024 (date) — Expected closing period
FAQ
What specific assets are included in the sale of the SCD technology?
The filing states that the 'Selective Cytopheretic Device (SCD) technology and related assets' are being sold, but does not provide a detailed list of specific assets.
Who is the unaffiliated third party purchasing the SCD technology?
The filing does not disclose the name of the unaffiliated third party purchasing the SCD technology.
What is the expected financial impact of this sale on SeaStar Medical?
The filing does not provide specific financial terms or the expected financial impact of the sale.
What are SeaStar Medical's other business segments that they will now focus on?
The filing mentions a strategic shift to focus on 'other business segments' but does not specify what those segments are.
What is the rationale behind SeaStar Medical's decision to sell the SCD technology?
The filing states the sale is part of SeaStar Medical's 'strategic shift to focus on its other business segments'.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 15.6 · Accepted 2024-07-09 16:14:06
Key Financial Figures
- $0.0001 — ich registered Common Stock par value $0.0001 per share ICU The Nasdaq Stock Mark
- $11.50 — sable for one share of Common Stock for $11.50 per share ICUCW The Nasdaq Stock Ma
Filing Documents
- icu-20240705.htm (8-K) — 42KB
- 0000950170-24-082415.txt ( ) — 189KB
- icu-20240705.xsd (EX-101.SCH) — 47KB
- icu-20240705_htm.xml (XML) — 6KB
01 — Other Events
Item 8.01 — Other Events On July 5, 2024, Forrest A K Wells (the "Plaintiff"), a purported stockholder of SeaStar Medical Holding Corporation, a Delaware Corporation (the "Company'), filed a putative class action complaint in the United States District Court for the State of Colorado (the "Class Action"), alleging that the Company and its management members made material misstatements or omissions regarding the Company's business and operations, including disclosures relating to FDA approval of product candidates of the Company, allegedly culminating in the restatement of the Company's consolidated financial statements as disclosed in the Form 8-K filed on March 27, 2024. The Class Action asserts claims under Section 10(b) of the Exchange Act against the Company, its Chief Executive Officer and former Chief Financial Officer (collectively, the Defendants"), as well as claims under Section 20(a) of the Exchange Act against the Defendants. Among other remedies, the Class Action seeks to recover compensatory and other damages. The Company intends to vigorously defend the action.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SeaStar Medical Holding Corporation By: /s/ Eric Schlorff Date: July 9, 2024 Name: Eric Schlorff Title: Chief Executive Officer